Puma Biotechnology Inc Common Stock PBYI
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T14:41:27.113Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T14:36:55.066643165Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T14:41:26.250665+00:00
Puma Biotechnology Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.46 | 175.8% | 53.9% | 7.86 | 183.4% | 28.9% |
| 25Δ | 8.39 | 167.1% | 24.6% | |||
| 30Δ | 12.25 | 116.4% | 23.2% | 8.93 | 150.8% | 20.2% |
| 35Δ | 11.87 | 115.7% | 20.7% | 9.46 | 134.5% | 15.8% |
| 40Δ | 11.50 | 115.1% | 18.2% | 10.00 | 118.2% | 11.5% |
| 45Δ | 11.12 | 114.4% | 15.7% | 10.39 | 119.2% | 10.3% |
| 50Δ | 10.75 | 113.8% | 13.2% | 10.79 | 120.2% | 9.1% |
| 55Δ | 10.37 | 113.1% | 10.7% | 11.18 | 121.3% | 7.9% |
| 60Δ | 10.00 | 112.5% | 8.2% | 11.58 | 122.4% | 6.7% |
| 65Δ | 9.62 | 111.7% | 7.1% | 11.97 | 123.5% | 5.5% |
| 70Δ | 9.25 | 110.9% | 6.0% | 12.36 | 124.6% | 4.3% |
| 75Δ | 8.87 | 110.0% | 4.9% | 13.02 | 126.4% | 3.4% |
| 80Δ | 8.49 | 109.2% | 3.8% | 13.80 | 128.7% | 2.5% |
20Δ
- Pseudo strike
- 15.46
- IV
- 175.8%
- B/E move
- 53.9%
- Pseudo strike
- 7.86
- IV
- 183.4%
- B/E move
- 28.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.39
- IV
- 167.1%
- B/E move
- 24.6%
30Δ
- Pseudo strike
- 12.25
- IV
- 116.4%
- B/E move
- 23.2%
- Pseudo strike
- 8.93
- IV
- 150.8%
- B/E move
- 20.2%
35Δ
- Pseudo strike
- 11.87
- IV
- 115.7%
- B/E move
- 20.7%
- Pseudo strike
- 9.46
- IV
- 134.5%
- B/E move
- 15.8%
40Δ
- Pseudo strike
- 11.50
- IV
- 115.1%
- B/E move
- 18.2%
- Pseudo strike
- 10.00
- IV
- 118.2%
- B/E move
- 11.5%
45Δ
- Pseudo strike
- 11.12
- IV
- 114.4%
- B/E move
- 15.7%
- Pseudo strike
- 10.39
- IV
- 119.2%
- B/E move
- 10.3%
50Δ
- Pseudo strike
- 10.75
- IV
- 113.8%
- B/E move
- 13.2%
- Pseudo strike
- 10.79
- IV
- 120.2%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- 10.37
- IV
- 113.1%
- B/E move
- 10.7%
- Pseudo strike
- 11.18
- IV
- 121.3%
- B/E move
- 7.9%
60Δ
- Pseudo strike
- 10.00
- IV
- 112.5%
- B/E move
- 8.2%
- Pseudo strike
- 11.58
- IV
- 122.4%
- B/E move
- 6.7%
65Δ
- Pseudo strike
- 9.62
- IV
- 111.7%
- B/E move
- 7.1%
- Pseudo strike
- 11.97
- IV
- 123.5%
- B/E move
- 5.5%
70Δ
- Pseudo strike
- 9.25
- IV
- 110.9%
- B/E move
- 6.0%
- Pseudo strike
- 12.36
- IV
- 124.6%
- B/E move
- 4.3%
75Δ
- Pseudo strike
- 8.87
- IV
- 110.0%
- B/E move
- 4.9%
- Pseudo strike
- 13.02
- IV
- 126.4%
- B/E move
- 3.4%
80Δ
- Pseudo strike
- 8.49
- IV
- 109.2%
- B/E move
- 3.8%
- Pseudo strike
- 13.80
- IV
- 128.7%
- B/E move
- 2.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 99.57% | |
| 81.08% | |
| 95.35% | |
| 88.94% | |
| 116.95% | |
| 112.56% | |
| 101.99% | |
| 80.32% |
Biotechnology
PCVX
Description unavailable
More →PDSB
Description unavailable
More →PEPG
Description unavailable
More →PGEN
Description unavailable
More →PHAT
Description unavailable
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →